Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Retaane® in Age-Related Macular Degeneration

This study has been completed.
Sponsor:
Information provided by:
Rudolf Foundation Clinic
ClinicalTrials.gov Identifier:
NCT00569569
First received: December 5, 2007
Last updated: December 6, 2007
Last verified: December 2007

December 5, 2007
December 6, 2007
February 2006
Not Provided
Increase in VA [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00569569 on ClinicalTrials.gov Archive Site
Decrease in Macula Edema [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Retaane® in Age-Related Macular Degeneration
Retaane® in Age-Related Macular Degeneration

The treatment of fibrotic choroidal neovascular lesions with presence of residual peripheral activity in age related macular degeneration currently presents a great challenge. With visual loss threatening, there are only very few therapeutic options.

While these patients are neither suitable for laser therapy nor for photodynamic therapy with Verteporfin, antiangiogenic drugs applied intravitreally are now available.

Some patients however reject this therapeutic option because of potential complications such as endophthalmitis and the frequency of necessary injections. 20 patients who rejected intravitreal therapy were treated with Anecortave acetate (Retaane®) which was applied as a juxtascleral depot injection.

Not Provided
Interventional
Phase 2
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Age Related Macular Degeneration
Drug: juxtascleral depot injection of Retaane
juxtascleral depot injection of Retaane
Experimental: 1
Patients treated with Retaane
Intervention: Drug: juxtascleral depot injection of Retaane
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
March 2007
Not Provided

Inclusion Criteria:

  • rejection of intravitreal injections
  • presence of fibrotic choroidal neovascular lesions with presence of residual peripheral activity in age related macular degeneration

Exclusion Criteria:

  • conditions precluding judgement of the fundus
Both
20 Years to 90 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00569569
RFC012007
No
Not Provided
Rudolf Foundation Clinic
Not Provided
Study Chair: Susanne Binder, M.D. no affiliation
Rudolf Foundation Clinic
December 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP